Uso dos inibidores de SGLT2 no tratamento da insuficiência cardíaca / Use of SGLT2 inhibitors in the treatment of heart insufficiency

Thais de Paula Silva Pilio, Marina Pithon Costa Souza, Milena Pereira Santos, Murilo Silva, Otávio Lima dos Reis, Paula Vanessa Carvalho Silva, Paulo César da Silva Júnior, Jhonson Tizzo Godoy

Abstract


INTRODUÇÃO: Recentemente, pesquisas sobre os Inibidores do Cotransportador de Sódio-Glicose 2, antes utilizados apenas no tratamento de Diabetes Mellitus do tipo 2, evidenciaram resultados positivos para o tratamento da Insuficiência Cardíaca.  METODOLOGIA: Trata-se de uma revisão de literatura, com busca de estudos nas bases de dados PUBMED, UPTODATE, SCIENCE DIRECT E MEDLINE. Os descritores usados foram “heart failure”, “heart failure redution ejection fraction”, “sodium-glucose transporter 2 inhibitors”, “sodium-glucose linked co-transporter 2 inhibitor”, “dapagliflozin”. Foram incluídos artigos científicos completos, em inglês, publicados entre 2016 e 2020. RESULTADOS: Os artigos analisados concordam que existem benefícios no uso dos inibidores de SGLT2 no tratamento da IC. DISCUSSÃO: A descoberta dos benefícios terapêuticos de alguns hipoglicemiantes em pacientes co-portadores de DM2 e IC iniciou a investigação sobre a ampliação do uso desses medicamentos em pacientes não diabéticos com IC. Os inibidores de SGLT2 se mostraram a classe de hipoglicemiantes mais eficaz e segura para esse fim. CONCLUSÃO: A prevalência de IC vêm aumentando mundialmente, devido à transição demográfica. Embora a IC seja uma condição distinta, quando comparada à DM2, a mesma demonstrou sofrer impactos relevantes com relação aos fármacos que visam diminuir a glicose. Mais estudos devem ser realizados sobre a temática.


Keywords


Insuficiência cardíaca, Agentes hipoglicemiantes, Tratamento, Diabetes.

References


AYUB-FERREIRA, SM; et al. Diretriz de Assistência Circulatória Mecânica da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. v. 107, p. 1-33, 2016.

COLUCCI, W. Secondary pharmacologic therapy in heart failure with reduced ejection fraction (HFrEF) in adults. UpToDate. 2021.

CONNELLY, K.A., et al. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020.

DOCHERTY, K.F., et al. Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. v. 14, n. 17, p. 1623-1632. 2020.

FRANCISCO, P. M. S. B., et al. Prevalence and co-occurrence of modifiable risk factors in adults and older people. Revista de Saúde Pública, v. 53, p. 86, 2019.

GIVERTZ, M; COLUCCI, W. Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action. UpToDate. 2020.

IMPRIALOS K.P., et al. The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, v.10, n.11, p. 1251-1261, 2017.

LYTVYN Y., et. al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation, v. 136, n. 17, p. 1643-1658, 2017.

MADDOX, T.M., et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021.

MARTINEZ, F. A.; et. al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. v. 141, n. 2, p. 100-111. 2020

MCMURRAY, J.; et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure. v. 21,n. 5, p. 665-675, 2019.

NAKAGAWA Y., et al. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agentes for treatment of non-diabetic heart failure patients. Journal of Cardiology. v. 76, n.2, p.123-131, 2020.

PACKER, M., et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. v. 383, n. 15, p. 1413-1424. 2020.

PRADHAN, A.; et al. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care. v. 8, n. 6, p. 1855-1862, 2019.

TRAVESSOS, G.F.; COELHO, A.B.; ARENDS-KUENNING, M. P. The elderly in Brazil: demographic transition, profile, and socioeconomic condition. Revista Brasileira de Estudos de População. v. 37, p. 1-27, 2020.

VADUGANATHAN, M., et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020.

VERMA, S; MCMURRAY, J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. v. 61, p. 2108-2117, 2018.

YANG D., et al. Comparative outcomes of heart failure among existent classes of anti-diabetic agentes: a network meta-analysis of 171,253 participants from 91 randomized controlled trials. Cardiovascular Diabetology. v. 18, n. 47, 2019.

ZANNAD, F., et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. v. 396, p. 819-829, 2020.

ZELNIKER, T.A., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. v. 5, n. 393, p. 31-39. 2019.




DOI: https://doi.org/10.34119/bjhrv4n2-010

Refbacks

  • There are currently no refbacks.